Vimarsana
Biggest News Aggregation in the World

Page 2 - Adjuvant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adjuvant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adjuvant Today - Breaking & Trending Today

Dr Bazhenova on Perioperative Treatment Selection in EGFR– or ALK-Mutated NSCLC - Vimarsana News

Dr Bazhenova on Perioperative Treatment Selection in EGFR– or ALK-Mutated NSCLC

Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.

Dr Tina Cascone Details Impact of Nivolumab Chemo-Immunotherapy on NSCLC - Vimarsana News

Dr Tina Cascone Details Impact of Nivolumab Chemo-Immunotherapy on NSCLC

Tina Cascone, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses the impact of the CheckMate 77T study on the treatment approach for non–small cell lung cancer (NSCLC).

Source: ajmc.com
FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC - Vimarsana News

FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC

The FDA has approved pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment for patients with resectable non–small cell lung cancer.

Protecting Your Cotton Investment - AG INFORMATION NETWORK OF THE WEST - Vimarsana News

Protecting Your Cotton Investment - AG INFORMATION NETWORK OF THE WEST

A lot of inputs, both monetary and calendar, go into your cotton crop each year. Today we’re focusing in on making the most of those investments during cotton defoliation with Davis Durham, Helena Agri-Enterprises.

Source: aginfo.net
Benefits of Combination Therapy in mNSCLC - Vimarsana News

Benefits of Combination Therapy in mNSCLC

Specialists engage in a conversation regarding the treatment duration and the effectiveness of the current two-year approach.

Source: ajmc.com